Actively Recruiting
Randomized Study of ITI-1284 Versus Placebo for Agitation in Alzheimers Dementia Evaluating Safety and Efficacy
Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03
320
Participants Needed
71
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284 in patients experiencing agitation associated with Alzheimers dementia. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to understand how ITI-1284 affects agitation symptoms in this population. Participants receive either ITI-1284 at doses of 10 mg or 20 mg as a rapidly disintegrating tablet taken once daily under the tongue, or a matching placebo tablet taken the same way. The study uses a flexible-dose design and assigns participants randomly to one of the two groups. Treatment is administered daily during the trial. Throughout the study, participants agitation is measured using the Cohen-Mansfield Agitation Inventory total score at Week 12 as the primary outcome. Additional assessments include the Clinical Global Impression-Severity score at Week 12. Participants are monitored for safety and tolerability, and the study lasts until completion around December 2027.
CONDITIONS
Brief Title
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here